NASDAQ:FATE - Fate Therapeutics Stock Price, Forecast & News

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics Inc (NASDAQ:FATE) issued its quarterly earnings data on Tuesday, November, 5th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.38) by $0.02. The biopharmaceutical company earned $2.43 million during the quarter, compared to the consensus estimate of $1.75 million. Fate Therapeutics had a negative net margin of 900.24% and a negative return on equity of 48.94%. Fate Therapeutics's revenue for the quarter was up 136.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.31) EPS. View Fate Therapeutics' Earnings History.

Fate Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Fate Therapeutics.

16 brokerages have issued 12-month price targets for Fate Therapeutics' stock. Their forecasts range from $20.00 to $33.00. On average, they anticipate Fate Therapeutics' stock price to reach $25.56 in the next year. This suggests that the stock has a possible downside of 0.1%. View Analyst Price Targets for Fate Therapeutics.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.

Headlines about FATE stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fate Therapeutics earned a news sentiment score of 0.8 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an impact on the stock's share price in the next several days. View News Stories for Fate Therapeutics.

Some companies that are related to Fate Therapeutics include Moderna (MRNA), argenx (ARGX), Repligen (RGEN), bluebird bio (BLUE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Momenta Pharmaceuticals (MNTA), Audentes Therapeutics (BOLD) and Acceleron Pharma (XLRN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), Energous (WATT), Juno Therapeutics (JUNO), Sangamo Therapeutics (SGMO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Immunomedics (IMMU), Neurocrine Biosciences (NBIX), Crispr Therapeutics (CRSP) and Exelixis (EXEL).

Fate Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include California Public Employees Retirement System (0.16%), Columbus Circle Investors (0.05%), TIAA FSB (0.03%) and Lindbrook Capital LLC (0.00%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc. View Institutional Ownership Trends for Fate Therapeutics.

FATE stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors and California Public Employees Retirement System. Company insiders that have sold Fate Therapeutics company stock in the last year include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker and J Scott Wolchko. View Insider Buying and Selling for Fate Therapeutics.

FATE stock was purchased by a variety of institutional investors in the last quarter, including TIAA FSB and Lindbrook Capital LLC. View Insider Buying and Selling for Fate Therapeutics.

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of FATE stock can currently be purchased for approximately $25.58.

Fate Therapeutics has a market capitalization of $1.93 billion and generates $4.74 million in revenue each year. The biopharmaceutical company earns $-66,600,000.00 in net income (profit) each year or ($1.19) on an earnings per share basis. Fate Therapeutics employs 104 workers across the globe.View Additional Information About Fate Therapeutics.

The official website for Fate Therapeutics is http://www.fatetherapeutics.com/.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]